Journal of Allergy and Clinical Immunology

Papers
(The H4-Index of Journal of Allergy and Clinical Immunology is 76. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan1496
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19740
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19522
2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group427
Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2423
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials383
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial344
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19279
Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis269
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study264
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells254
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia251
Eosinophil responses during COVID-19 infections and coronavirus vaccination244
Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China238
Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19229
Type I IFN immunoprofiling in COVID-19 patients215
Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study207
Complement activation in patients with COVID-19: A novel therapeutic target202
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection184
COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience181
Influence of immune aging on vaccine responses180
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management178
Epithelial barriers in allergy and asthma176
Environmental factors in epithelial barrier dysfunction175
Association of asthma and its genetic predisposition with the risk of severe COVID-19163
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study158
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council153
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity150
Drug allergy: A 2022 practice parameter update149
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial149
Rhinitis 2020: A practice parameter update148
IL-6–based mortality risk model for hospitalized patients with COVID-19146
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial145
Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1139
JAK inhibitors in the treatment of atopic dermatitis135
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19131
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study123
Food allergy across the globe121
Air pollution, racial disparities, and COVID-19 mortality121
Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type–specific immune regulation in atopic dermatitis117
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines117
New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation116
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis114
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease109
Asthma-associated risk for COVID-19 development108
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon108
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial107
Asthma among hospitalized patients with COVID-19 and related outcomes105
The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease105
Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS102
Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses102
Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score101
Biomarkers of severity and threshold of allergic reactions during oral peanut challenges100
Obesity and asthma98
Cutaneous barrier dysfunction in allergic diseases97
Regulating T-cell differentiation through the polyamine spermidine94
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis94
COVID-19: Unanswered questions on immune response and pathogenesis90
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)90
Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS189
Staphylococcus epidermidis protease EcpA can be a deleterious component of the skin microbiome in atopic dermatitis88
Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach87
Randomized trial of early infant formula introduction to prevent cow’s milk allergy86
Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype86
Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction83
Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: A Work Group Report of the AAAAI Committee on the Underserved83
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study83
Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)82
SARS-CoV-2 antibody testing—questions to be asked82
Mechanisms and pathogenesis of chronic rhinosinusitis81
Autoimmune chronic spontaneous urticaria81
COVID-19–associated multisystem inflammatory syndrome in children (MIS-C): A novel disease that mimics toxic shock syndrome—the superantigen hypothesis80
Clinical testing for COVID-1980
Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer78
Climate change and global issues in allergy and immunology77
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies77
Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype76
Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy76
0.034682989120483